Study for a Magnetic Endourethral Sphincter Against Stress Urinary Incontinence

NCT ID: NCT05449639

Last Updated: 2023-03-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-17
• Study Completion Date: 2023-12-31

Brief Summary

A second no-random open interventional pilot study sponsored by Relief srl

Detailed Description

The first pilot study, where the device was implanted on 6 human patients for 28 days, demonstrated that the magnetic urethral sphincter was successfully implanted and explanted in all patients (5 males and 1 female). All the procedures have proven ease of implantation and removal (6/6, 100%), decent simplicity of the activation and de-activation system and restoring an acceptable urinary continence. The majority of patients (5/6, 83.4%) reported a good tolerability of the sphincter. Unfortunately, only 1/6 patient (16.7%) was able to complete the 28 days cycle with the urinary sphincter in place: in the other 5 patients (83.3%) the sphincter migrated into the bladder due to the lack of a hooking system, which was not considered relevant in the design phase and during previous cadaver tests. This migration seemed caused by an oversized external magnet, producing a large force also in not optimized positioning, and by the anatomic variability of patients' urethral caliber. In one patient the sphincter stayed perfectly in place for all the 28 days; its position was checked after 10 days of the implantation by suprapubic ultrasound scan. This patient referred excellent urinary continence also with the sphincter in the "opened" configuration (without using the external magnet but by relying only on the valve flexibility), without urinary leaks during daily activities and sport activities too. No severe side effects or complications or infections occur after the migration of the device in the bladder and during its implantation/removal.

The final analysis of data and questionnaires showed that, to adapt the magnetic urethral sphincter to the clinical practice, a re-design is necessary in order to improve the anchoring system and to optimize the magnetic activation system, avoiding bladder migration of the device.

In this framework Relief re-designed the device by optimizing the external magnet, by improving the proximal anchoring system and by providing with a distal anchoring system. The new design was validated by test bench and on cadaver anatomies.

The primary objectives of the study were to assess the safety and reproducibility of the implantation of the magnetic endo-urethral sphincter, if the procedure was well tolerated by the patients, and if possible irritation symptoms due to the device presence emerged in patients with severe stress urinary incontinence where standard medical treatments failed.

Conditions

Urinary Incontinence

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Main group

A second no-random open interventional pilot study sponsored by Relief srl. The primary objectives of the study were to assess the safety and reproducibility of the implantation of the magnetic endo-urethral sphincter, if the procedure was well tolerated by the patients, and if possible irritation symptoms due to the device presence emerged in patients with severe stress urinary incontinence where standard medical treatments failed. The device will be implanted by endoscopic procedure by a standard resectoscope. Up to 20 patients of both gender affected by severe stress urinary incontinence will be involved in the study by means of prospective enrollment.

Group Type: EXPERIMENTAL

Relief implantation

Intervention Type: DEVICE

The device will be implanted by endoscopic procedure by a standard resectoscope.

Interventions

Relief implantation

The device will be implanted by endoscopic procedure by a standard resectoscope.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Male patients aged from 45 to 85 years-old suffering from secondary Stress Urinary Incontinence (SUI) to prostate surgery in which medical and rehabilitative treatment have failed;

2. women patients aged from 45 to 85 years-old suffering from SUI in which medical, rehabilitative and surgical treatment have failed;

3. sterile urine culture;

4. urodynamic test with evidence of sphincter dysfunction, Valsalva Leak Point Pressure (VLPP) < 60 cm H2O (water) and exclusion of detrusor over-activity;

5. flexible cystoscopy demonstrating sphincter dysfunction and excluding stenosis of the urethra or vesicourethral anastomosis.

Exclusion Criteria

1. No-autonomous patients;

2. People where the use of magnetic field is not suggested (i.e. patients with pacemaker).

3. Patients with urinary infections;

4. Patients with intolerances to the materials included in the sphincter or to expected drug subministration.

5. Patients already participating a clinical study within the last 30 days.

6. Patients that already have devices/solutions or part of them for the treatment of urinary incontinence.

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Donawa Lifescience

UNKNOWN

Sponsor Role: collaborator

Relief srl

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Casa di Cura San Camillo

Forte dei Marmi, Lucca, Italy

Site Status: RECRUITING

Azienda Ospedaliero Universitaria Pisana UO Urologia

Pisa, , Italy

Site Status: RECRUITING

Policlinico Universitario Campus Bio-Medico UOC Urologia

Roma, , Italy

Site Status: RECRUITING

Countries

Italy

Facility Contacts

Massimo Cecchi, Dott.

Role: primary

mascecchi@gmail.com

Giorgio Pomara, Prof.

Role: primary

g.pomara@ao-pisa.toscana.it

Rocco Papalia, Prof.

Role: primary

rocco.papalia@unicampus.it

Other Identifiers

CIP-002

Identifier Type: -

Identifier Source: org_study_id